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Methods and Results We analyzed 40 endomyocardial biopsy specimens from 25 cardiac transplant patients and 8 specimens from patients undergoing cardiac surgery. Patients with evidence of infection or malignancy were excluded. Specimens were stained with monoclonal antibodies against ICAM-1, E-selectin, VCAM-1, and PECAM-1 (which labels all vessels). ICAM-1 expression was assessed by counting ICAM-1-positive vessels and dividing by the total number of vessels (measured by PECAM staining). Specimens were scored as positive or negative for VCAM-1 and E-selectin.
We also determined whether serum-soluble ICAM-1 levels (sICAM) correlated with rejection by evaluating 145 serum specimens from 48 cardiac transplant patients and 8 specimens from patients undergoing diagnostic cardiac catheterardiac transplantation has become widely ac-C cepted as therapy for end-stage heart disease.
Despite major advances in the field of transplant immunology over the past decade, attempts to design safe, effective, and highly specific immunosuppressive agents remain hampered by incomplete understanding of the pathophysiology of allograft rejection.
Over the past decade, it has become clear that an important component of any inflammatory response is the ability of leukocytes to effectively interact both with other leukocytes and with the vascular endothelium. These interactions are now known to be mediated by specific cell surface receptors called cellular adhesion molecules (CAMs). [1] [2] [3] [4] [5] [6] It is hypothesized that sets of CAMs function in a programmed and sequential fashion, allowing effective and precise cell-cell interactions. For example, leukocyte-endothelium interactions are postulated to begin with the transition from rapid flow of leukocytes over the vascular endothelium to leuko-cyte "rolling," mediated by members of the selectin family present on leukocytes (L-selectin) and endothelial cells (P-selectin and E-selectin). After this initial "tethering," firm adhesion is established by binding of leukocyte integrins, such as LFA-1, Mac-i ("CD18 integrins"), and VLA-4 (a4bl), to members of the immunoglobulin superfamily (ICAM-1, ICAM-2, and VCAM-1), which are expressed on endothelial cells, and, in the case of ICAM-1 and -2, on other leukocytes. This interaction between leukocyte and endothelial cell CAMs is a prerequisite for the migration of white blood cells into areas of inflammation. Similarly, leukocyteleukocyte interactions mediated by CAMs are required for antigen presentation and T and B cell interactions.2
Because the process of transplant rejection involves migration of recipient leukocytes into graft tissue, it is not surprising that a number of recent studies have suggested a relation between CAMs and cardiac allograft rejection. [8] [9] [10] [11] [12] [13] [14] [15] [16] Although these studies are both provocative and interesting, a number of questions remain. First, the degree of rejection has not been optimally categorized or quantitated; most previous investigations have labeled biopsy specimens as either rejection" or "+rejection" for comparison. The present study was designed to evaluate the expression of CAMs in human cardiac allograft rejection. We had three primary aims: (1) to quantitatively evaluate the expression of the endothelial CAMs-ICAM-1, VCAM-1, and E-selectin-in native myocardium as well as cardiac allografts, (2) to determine if increased CAM expression correlates with more severe degrees of rejection, and (3) to evaluate whether sICAM levels from transplant recipients correlate with histological evidence of rejection on simultaneously obtained endomyocardial biopsy specimens.
Methods

Immunohistochemical Studies Subjects and Specimens
We studied 40 endomyocardial biopsy specimens from 25 cardiac transplant patients as well as 8 cardiac biopsies from patients without clinical evidence of congestive heart failure who were undergoing open heart surgery. (Patients with heart failure were excluded from the control group in light of recent data showing that patients with chronic congestive heart failure may have elevated serum levels of tumor necrosis factor.21) The mean age of the transplant patients was 53.8 years (range, 21 to 65 years), and the mean age of nontransplant patients was 64 years (range, 32 to 76 years). All transplant patients were treated with immunosuppressive therapy, including cyclosporine A, azathioprine, and prednisone, as is customary at our institution. Previous investigations have identified anti-PECAM-1 antibodies as highly reliable in staining all human vascular beds.13'27'28 Therefore, to assess the total number of vessels per specimen area, we recorded and averaged the number of vessels stained with the anti-human PECAM-1 monoclonal antibody 5.6E for three randomly selected fields of 0.25 mm2 (x 10). A similar procedure was followed to evaluate the number of vessels per unit area staining with each of the above-named antibodies. To assess intraobserver variation, the one observer repeated assessments of CAM expressions on the same specimens, and the results were compared. To assess interobserver variability, a second investigator assessed CAM expression on the same specimens, and these results were compared with those of the first observer.
Statistical Analysis
For ICAM-1 staining, intergroup differences were determined by ANOVA followed by the modified Tukey's test. Fisher's exact test was used to analyze the results of staining for VCAM-1 and E-selectin. For intraobserver and interobserver variability, the correlation coefficient for assessments of ICAM-1 staining was determined.
sICAM Subjects and Specimens
One hundred forty-five specimens from 48 cardiac transplant patients undergoing routine follow-up endomyocardial biopsy and 8 specimens from patients undergoing cardiac catheterization to rule out coronary artery disease were evaluated. The mean age of the transplant patients was 54.8 years (range, 19 to 67 years). Exclusionary criteria were as noted above. As a result of infection, 27 additional specimens were excluded, whereas none were excluded for malignancy. Blood samples were obtained from each patient and spun at 3000g for 10 minutes. The serum was removed and stored at -70°C until use. Endomyocardial biopsy specimens (transplant patients only) were stained with HE and scored as above. Cardiac histology of control patients was assumed to be within normal limits.
ELISA
Serum levels of ICAM-1 were assessed using a doubleantibody ELISA kit (ICAM-1 Test Kit, T Cell Diagnostics). Briefly, the kit provided 96-well ELISA plates coated with murine anti-human ICAM-1 antibody, as well as standards containing known concentrations of ICAM-1, and all necessary solutions. Wells (except those used as blanks) were overlaid with 25 mL of standards containing a known concentration of ICAM-1 (0 to 8.94 ng/mL) or 25 mL of samples that were diluted 1:100 with BSA/thimerosal. Then, 75 mL of horseradish peroxidase-conjugated anti-human ICAM antibody was added to all wells except blanks. Plates were gently agitated for 15 seconds and incubated at room temperature for 2 hours on a rotator at 150 rpm. Wells were aspirated and then washed three times with 350 mL of PBS/surfactant. Chromogen (100 mL) was added to each well. (Chromogen was prepared by adding four chromogen tablets to 20 mL of urea/peroxide/thimerosal.) Plates were incubated uncovered 4L of stop solution (2 N H2S04) was added to each well. OD490 was read for each well, and a standard curve was derived from known concentrations of sICAM. All specimens were analyzed in duplicate and averaged, and the estimate of sICAM in experimental specimens was derived from comparison with the standard curve values. To determine the variability between kits as well as the effect of storage on sICAM-1 levels in serum, 42 specimens were assayed again using a second kit 2 months after the first assay.
Statistical Analysis
Differences among groups were determined by ANOVA. Results of repeat assays performed on 42 specimens were compared with the initial assay results using correlation coefficients.
Results
Immunohistochemical Studies
Specimens were grouped according to histological appearance of the HE specimens (normal, negative, mild, focal moderate, or moderate/severe).
PECAM-1
The vessels within each biopsy section were identified using the anti-PECAM-1 antibody, 5.6E (Figs 1A and 1C). There was strong staining of the microvessels running adjacent to each myofibril as well as the larger venules and arterioles. This was found in all specimens, regardless of the presence or absence of rejection. ICAM-1 Fig 1B shows an example of ICAM-1 staining in a specimen without evidence of rejection (specimen 8). This can be compared with Fig 1D, which shows ICAM-1 staining in a specimen with moderate cellular rejection (specimen 34). ICAM-1 staining was noted in 58% of the vessels present in specimen 8 and 95% of the vessels in specimen 34. In general, ICAM-1 was found to be present on perimyocytic capillaries and larger vessels. No staining of the myocardium was noted in any specimen.
The degree of ICAM-1 staining for each group of biopsies is summarized in Table 1 and Fig 2. The following intergroup differences were noted. Specimens with evidence of moderate or severe rejection demonstrated significantly greater ICAM-1 expression than normal specimens, transplant specimens without rejection, and transplant specimens with mild rejection (all P<.01). Specimens with focal moderate rejection showed significantly greater ICAM-1 expression than normal specimens and specimens with mild rejection (both P<.05). Most important, when specimens with histologically significant rejection (focal moderate or moderate/severe) were compared with specimens without significant rejection (negative or mild rejection), there was a marked difference in ICAM-1 expression (P<.01). Assessment of ICAM-1 expression was reproducible with excellent intraobserver (r=.96) and interobserver (r=.92) variability.
VCAM-1 and E-Selectin
In contrast to the typical pattern of ICAM-1 expression, staining for VCAM-1 and E-selectin was patchy and infrequent. These CAMs were seen exclusively on noncapillary vessels, with the exception of one specimen with evidence of severe rejection that demonstrated for 30 minutes at room temperature. To end the reaction, 50 trace capillary staining with the anti-E-selectin anti- observer variability (96% and 92%, respectively). Using this method of analysis, we found that specimens with evidence of moderate-to-severe rejection showed higher levels of ICAM-1 expression than nontransplanted specimens from healthy individuals and allograft specimens without significant rejection. Specimens with focal moderate rejection (grade 2) also showed increased ICAM-1 expression compared to with specimens from healthy individuals and specimens with mild rejection (grades 0, 1A, and 1B). Interestingly, if specimens with mild rejection were eliminated from this comparison, the difference between specimens with focal moderate rejection and specimens with no rejection (grade 0 alone) was not significant. This was likely due to one "outlying" specimen in the negative group; specimen 3 had 77% ICAM-1-positive vessels (this frozen-section specimen from which the assessment of ICAM-1 staining was made did not show more inflammation than the Formalin-fixed specimens obtained at the time of biopsy or than specimens from other biopsies in the negative group). Of note, no differences were seen between nontransplanted specimens and specimens with no rejection or with mild rejection. Most significantly, ICAM-1 expression appears to be a fairly accurate marker of clinically significant rejection, as specimens with significant rejection showed substantially greater ICAM-1 expression than transplant specimens without significant rejection (negative or mild rejection). In fact, a value for ICAM-1-positive vessels of >80% predicts significant rejection (necessitating treatment) with a sensitivity and specificity of 85% and 95%, respectively.
In contrast to our findings with ICAM-1, the expression of the two other CAMs examined (VCAM-1 and E-selectin) was much more limited and generally was restricted to fewer than five vessels per biopsy. In the present study, we found no difference between groups with respect to E-selectin expression. VCAM-1 was more likely to be present in specimens with significant rejection than in specimens from healthy individuals; however, this CAM was not seen in all specimens with rejection. These limited expression patterns may be due to the fact that VCAM-1 and E-selectin tended not to be expressed on capillary vessels but rather on larger The expression of endothelial cell CAMs has been examined in several types of allograft tissue, including kidney, liver, and pancreas. Rejecting renal allografts have increased expression of ICAM-1 on tubular epithelial cells and vascular endothelium. 29 Brockmeyer et a130 recently demonstrated that VCAM-1 is induced on peritubular capillaries and upregulated on the tubular epithelium during renal transplant rejection. Rejecting hepatic allografts show upregulation of ICAM-1 on bile duct epithelium, hepatocytes, and vascular endothelium, which are the primary targets of the rejection process.31,32 VCAM-1 staining has been noted on some endothelial cells as well as a population of dendritic-like cells in rejecting hepatic and pancreatic allografts. 33 Our results can be compared with those of previous studies that have assessed the relation between cardiac allograft rejection and CAM expression (summarized in Table 3 ). This comparison is somewhat difficult because most researchers did not stratify specimens according to degree of rejection, nor did they note whether specimens demonstrated evidence of Quilty effect or previous biopsy artifact. Degree of staining was assessed qualitatively or as counts of stained structures per unit specimen area. Importantly, the presence of infection or malignancy was an exclusion criteria in our study so that causes of increased CAM expression other than rejection were eliminated. Our An upregulation of CAM expression in rejecting cardiac allografts seems logical in light of current understanding of the pathophysiology of transplant rejection. This is likely due to the release of inflammatory mediators such as interleukin-1, tumor necrosis factor-a, and interferon-y by immune cells infiltrating in the allograft. These factors lead to an upregulation of CAMs on various cells of the graft, a process that facilitates leukocyte transmigration and a full-scale immune assault on the foreign tissue. Leukocyte adhesion to explanted, rejecting murine cardiac allograft tissue has been shown to be impaired by anti-CAM antibodies, thus suggesting that increased CAM expression in allograft tissues is of critical significance. 38 Two of the most important goals of transplant immunology research remain improved diagnostic and therapeutic strategies for rejection. Unfortunately, given their unreliability, it appears that sICAM levels are not useful as a means of detecting rejection. However, the pattern of myocardial vascular CAM expression in rejection suggests other interesting possibilities, such as the use of radiolabeled anti-ICAM antibodies to noninvasively detect rejection. 39 Of even greater importance are the potential therapeutic modalities. Several studies have shown that monoclonal antibodies directed against various CAMs can prolong graft survival and prevent rejection.40-42 Anti-CAM-1 antibodies are being used in clinical trials of patients who received renal transplantation.
Study Limitations
The present study demonstrates a potentially useful quantitative approach for the determination of ICAM-1 expression on vascular endothelium of cardiac transplant patients as a function of the severity of rejection. Samples were obtained from patients with various degrees of rejection. Vigorous attempts were made to prospectively and retrospectively exclude samples from patients with infection or malignancy. Occult infection without signs, symptoms, and clinical parameters indicative of infection may have confounded the results of this study to some degree, but follow-up of the patients longitudinally after transplant has not revealed the development of any infection in the patients included in this study. This study did not sequentially study numerous samples from individual patients to determine the changes of CAMs over time. It is possible that some CAMs may be expressed before histological evidence of rejection by HE is present. However, at the time of focal moderate rejection, which likely precedes moderate or severe rejection, only ICAM-1 expression is elevated. Although the other CAMs may play a role in the very early stages of rejection, their expression does not appear enhanced with mild or focal moderate rejection from the results of our study.
Conclusions
In summary, our study supports a relation between ICAM-1 expression and cardiac allograft rejection. The role played by other CAMs, such as VCAM-1 and especially E-selectin, is less certain. Serum ICAM-1 levels do not appear to reflect tissue ICAM-1 expression in a straightforward way. Further understanding of the importance of CAM expression in the pathophysiology of allograft rejection may lead to novel diagnostic and therapeutic strategies.
